SOST and osteoporosis: It is noteworthy to mention that a meta-analysis has indicated that denosumab therapy is not associated with any adverse cardiovascular effects in patients with primary osteoporosis, while romosozumab, a humanized sclerostin inhibitor that increases bone formation and decreases bone resorption, may increase the risk of major adverse cardiovascular events in osteoporotic patients, particularly in elderly men and postmenopausal women [54].